Resolvin E1 protects the rat heart against reperfusion injury - PubMed (original) (raw)
. 2010 Jul;299(1):H153-64.
doi: 10.1152/ajpheart.01057.2009. Epub 2010 Apr 30.
Affiliations
- PMID: 20435846
- DOI: 10.1152/ajpheart.01057.2009
Free article
Resolvin E1 protects the rat heart against reperfusion injury
K T Keyes et al. Am J Physiol Heart Circ Physiol. 2010 Jul.
Free article
Abstract
The purpose of the present study was to assess whether resolvin E1 (RvE1), an anti-inflammatory mediator derived from eicosapentaenoic acid, would limit myocardial infarct size in the rat. The H9c2 cell line was used to assess whether RvE1 has direct protective effects on cardiomyocytes. In in vivo experiments, Male Sprague-Dawley rats underwent 30 min of ischemia/4 h of reperfusion. Before reperfusion, rats received intravenous RvE1 (0, 0.03, 0.1, or 0.3mg/kg). In in vitro experiments, H9c2 cells were incubated with RvE1 (0, 1, 10, 100, or 1000 nM). Cells were subjected to 18 h of incubation under normoxic conditions, 16 h of hypoxia, or 16 h of hypoxia and 2 h of reoxygenation. In vivo, RvE1 dose dependently reduced infarct size (30.7 +/- 1.7% of the area at risk in the control group and 29.1 +/- 1.6%, 14.7 +/- 1.3%, and 9.0 +/- 0.6% in the 0.03, 0.1, and 0.3 mg/kg groups, respectively, P < 0.001). In vitro, RvE1 increased viability and decreased apoptosis in a dose-dependent fashion in cells exposed to hypoxia or hypoxia/reoxygenation. A maximal effect was achieved at a concentration of 100 nM. RvE1 augmented phosphoinositide 3-kinase activity, attenuated caspase-3 activity, and augmented calcium-dependent nitric oxide synthase activity in cells exposed to hypoxia or hypoxia/reoxygenation. RvE1 increased Akt, ERK1/2, and endothelial nitric oxide synthase phosphorylation and attenuated the levels of activated caspase-3 and phosphorylated p38 levels. AG-1478, an EGF receptor tyrosine kinase inhibitor, blocked the protective effect of RvE1 both in vivo and in vitro and attenuated the RvE1-induced increase in Akt and ERK1/2 phosphorylation. In conclusion, RvE1, an anti-inflammatory mediator derived from eicosapentaenoic acid, has a direct protective effect on cardiomyocytes against ischemia-reperfusion injury and limits infarct size when administered intravenously before reperfusion.
Similar articles
- Pharmacological inhibition of PTEN limits myocardial infarct size and improves left ventricular function postinfarction.
Keyes KT, Xu J, Long B, Zhang C, Hu Z, Ye Y. Keyes KT, et al. Am J Physiol Heart Circ Physiol. 2010 Apr;298(4):H1198-208. doi: 10.1152/ajpheart.00915.2009. Epub 2010 Jan 22. Am J Physiol Heart Circ Physiol. 2010. PMID: 20097771 - Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size.
Ye Y, Keyes KT, Zhang CF, Perez-Polo JR, Lin Y, Birnbaum Y. Ye Y, et al. Cardiovasc Drugs Ther. 2010 Apr;24(2):107-20. doi: 10.1007/s10557-010-6227-y. Cardiovasc Drugs Ther. 2010. PMID: 20379769 - Current Updates on Potential Role of Flavonoids in Hypoxia/Reoxygenation Cardiac Injury Model.
Ali SS, Noordin L, Bakar RA, Zainalabidin S, Jubri Z, Wan Ahmad WAN. Ali SS, et al. Cardiovasc Toxicol. 2021 Aug;21(8):605-618. doi: 10.1007/s12012-021-09666-x. Epub 2021 Jun 10. Cardiovasc Toxicol. 2021. PMID: 34114196 Review. - Do platelets protect the heart against ischemia/reperfusion injury or exacerbate cardiac ischemia/reperfusion injury? The role of PDGF, VEGF, and PAF.
Voronkov NS, Maslov LN, Vyshlov EV, Mukhomedzyanov AV, Ryabov VV, Derkachev IA, Kan A, Gusakova SV, Gombozhapova AE, Panteleev OO. Voronkov NS, et al. Life Sci. 2024 Jun 15;347:122617. doi: 10.1016/j.lfs.2024.122617. Epub 2024 Apr 11. Life Sci. 2024. PMID: 38608835 Review.
Cited by
- The Role of Specialized Pro-Resolving Lipid Mediators in Inflammation-Induced Carcinogenesis.
Torres W, Pérez JL, Díaz MP, D'Marco L, Checa-Ros A, Carrasquero R, Angarita L, Gómez Y, Chacín M, Ramírez P, Villasmil N, Durán-Agüero S, Cano C, Bermúdez V. Torres W, et al. Int J Mol Sci. 2023 Aug 10;24(16):12623. doi: 10.3390/ijms241612623. Int J Mol Sci. 2023. PMID: 37628804 Free PMC article. Review. - Inflammation Resolution in the Cardiovascular System: Arterial Hypertension, Atherosclerosis, and Ischemic Heart Disease.
Gonzalez AL, Dungan MM, Smart CD, Madhur MS, Doran AC. Gonzalez AL, et al. Antioxid Redox Signal. 2024 Feb;40(4-6):292-316. doi: 10.1089/ars.2023.0284. Epub 2023 Aug 1. Antioxid Redox Signal. 2024. PMID: 37125445 Review. - Application of regulation of reactive oxygen species and lipid peroxidation to disease treatment.
Shichiri M, Suzuki H, Isegawa Y, Tamai H. Shichiri M, et al. J Clin Biochem Nutr. 2023 Jan;72(1):13-22. doi: 10.3164/jcbn.22-61. Epub 2022 Oct 18. J Clin Biochem Nutr. 2023. PMID: 36777080 Free PMC article. - Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches.
Soni SS, D'Elia AM, Rodell CB. Soni SS, et al. Drug Deliv Transl Res. 2023 Jul;13(7):1983-2014. doi: 10.1007/s13346-023-01290-2. Epub 2023 Feb 10. Drug Deliv Transl Res. 2023. PMID: 36763330 Free PMC article. Review. - Classes of Lipid Mediators and Their Effects on Vascular Inflammation in Atherosclerosis.
Lubrano V, Ndreu R, Balzan S. Lubrano V, et al. Int J Mol Sci. 2023 Jan 13;24(2):1637. doi: 10.3390/ijms24021637. Int J Mol Sci. 2023. PMID: 36675152 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous